Research Article

Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds

Ragi Jadimurthy, Shilpa Borehalli Mayegowda, S.Chandra Nayak, Chakrabhavi Dhananjaya Mohan, Kanchugarakoppal S. Rangappa

A R T I C L E  I N F O

Keywords: ESKAPE, Multidrug resistance, Natural compounds, Secondary metabolites

A B S T R A C T

The microorganisms that have developed resistance to available therapeutic agents are threatening the globe and multidrug resistance among the bacterial pathogens is becoming a major concern of public health worldwide. Bacteria develop protective mechanisms to counteract the deleterious effects of antibiotics, which may eventually result in loss of growth-inhibitory potential of antibiotics. ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter spp.) pathogens display multidrug resistance and virulence through various mechanisms and it is the need of the hour to discover or design new antibiotics against ESKAPE pathogens. In this article, we have discussed the mechanisms acquired by ESKAPE pathogens to counteract the effect of antibiotics and elaborated on recently discovered secondary metabolites derived from bacteria and plant sources that are endowed with good antibacterial activity towards pathogenic bacteria in general, ESKAPE organisms in particular. Abyssomicin C, allicin, anthracimycin, berberine, biochanin A, caffeic acid, daptomycin, kibdelomycin, piperine, platensimycin, plazomicin, taxifolin, teixobactin, and thymol are the major metabolites whose antibacterial potential have been discussed in this article.

1. Introduction

From 1940 to 1965 is the golden era in the field of antibiotics as many antimicrobials were discovered and introduced into modern medicine. The discovery of new antibiotics revolutionized modern medicine as these small molecules have been widely implemented in the treatment of bacterial diseases. Unfortunately, discontinuous or improper, or irregular intake and excessive usage of antibiotics have led to the emergence of antibiotic-resistant microorganisms. Antibiotic resistance is increasing at an alarming pace and has become one of the major health concerns of the globe due to various reasons including the availability of a limited number of antibiotics. According to the anti-biotic resistance threats report (2019) of the Centers for Disease Control and Prevention (CDC, United States), 2.8 million people are infected with antibiotic-resistant infection and more than 35,000 people die annually in the United States alone. The existence of drug-resistant pathogens came into recognition only in the last two decades. Lack of development of new antimicrobials is one of the key factors for the crisis in the medical field that has been denoted elsewhere [1]. The Center for Disease Dynamics, Economics, and Policy (CDDEP) have well-documented the global status of antibiotics policy to understand the resistance and need for newer antimicrobials [2]. It is a matter of serious concern that, significant progress has not been made in the discovery and development of new antibiotics in the previous three decades. Many pharmaceutical companies have committed towards the development of drugs for the treatment of non-communicable diseases which are of substantial economic interest [3]. On one hand, pathogens are gaining resistance gradually towards existing therapeutics and on the other hand, a feeble amount of efforts have been made in the discovery of new antibiotics. Therefore, it is the need of the hour to discover new antimicrobials which are potent against a broad spectrum of microorganisms including drug-resistant pathogens.

* Corresponding authors.
E-mail addresses: cd.mohan@yahoo.com (C.D. Mohan), rangappaks@gmail.com (K.S. Rangappa).

These authors contributed equally to this work.

https://doi.org/10.1016/j.btre.2022.e00728
Received 31 December 2021; Received in revised form 10 March 2022; Accepted 31 March 2022
Available online 4 April 2022
2215-017X/© 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Microorganisms develop an adaptive mechanism to survive in the favorable/adverse atmosphere and as a part of this, they subsequently develop several protective mechanisms to reduce their antibiotic susceptibility. This eventually leads to the loss of antibiotic potency and thus, making them ineffective for the treatment of bacterial infections. A group of microorganisms that possess multidrug resistance and virulence include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. causing nosocomial infections and contributing a lion’s share in hospital-acquired infections [4]. Louis B Rice gave the acronym for these pathogens as ESKAPE organisms and the following section discusses about the antibacterial resistance mechanisms of these pathogens [5].

2. ESKAPE pathogens

Hospital-acquired (nosocomial) infections can be caused by various microbes such as bacteria, fungi, viruses, parasites, and other agents. The transmission of these infections could be due to interpersonal communications between patients or with healthcare providers, through contaminated equipment, lack of proper sterilization measures, and many more [6]. Hospital-acquired infections may contribute to lengthier hospital stays, increased treatment-related expenses, and a high mortality rate [7]. The Infectious Diseases Society of America has grouped the bacterial pathogens responsible for hospital-acquired infections and referred to as “ESKAPE” pathogens. E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and Enterobacter spp. are the organisms that are grouped under ESKAPE pathogens and they can escape from the biocidal activity of antibacterial drugs. These organisms display a characteristic of multidrug resistance (MDR) and may pose a potentially fatal condition for immunocompromised individuals or patients with serious illness [6]. The World Health Organization (WHO) has recently included ESKAPE pathogens in the inventory of twelve bacteria which demands the development of new antibiotics urgently [8]. In a critical analysis, the multicriteria decision analysis method was used to prioritize antibiotic-resistant bacteria and classified bacteria into three categories (critical priority, high priority, and medium priority) depending on the need for the development of new antibiotics against antibiotic-resistant bacteria [8]. Among ESKAPE organisms, carbapenem-resistant A. baumannii and carbapenem-resistant P. aeruginosa were listed under critical priority, and vancomycin-resistant E. faecium (VREF) and methicillin/vancomycin resistant S. aureus (MRSA/VRSA) were categorised under high priority groups [8]. They also suggested the need for the development of new antibacterial agents against multidrug resistance (MDR)-tuberculosis, Gram-negative bacteria, antibiotic-resistant bacteria responsible for community-acquired infections such as Salmonella spp, Campylobacter spp, Neisseria gonorrhoeae, and Helicobacter pylori. The bacteria may develop MDR through various mechanisms including chemical alteration or breakdown of the drug, interference with influx and efflux of antibiotics, modification of drug target, and many more. In the below section, we have briefly discussed major mechanisms of drug resistance shown by ESKAPE organisms to escape from the antibiotics.

3. Major mechanisms of drug resistance acquired by ESKAPE organisms

MDR bacteria have acquired various defense mechanisms to protect
themselves from the bactericidal activity of antibiotics and some of the major drug-resistant mechanisms developed by ESKAPE organisms have been discussed in this section and graphical representation is provided in Fig. 1.

3.1. Chemical modification or breakdown of the drug

Bacteria express some crucial enzymes (such as β-lactamases) which offers them a survival benefit by chemically modifying or destroying the antibiotics. β-lactamases are some of the widely-studied enzymes in relevance to antibiotic resistance and they are characterized by their ability to cleave the amide bond of the four-membered β-lactam ring present in penicillins, cephalosporins, cephemycins, monobactams, and carbapenams [9]. Penicillinase, cephalosporinase, broad-spectrum β-lactamases, metallo-β-lactamases, extended-spectrum β-lactamases (ESBL), and carbapenemases are the major types of lactamases responsible for drug destruction which makes the antibiotic inactive and more than 2600 different β-lactamases have been identified so far [10]. The catalytic activity of some of these enzymes can be inhibited by compounds such as clavulanate, tazobactam, sulbactam, and ticarcillin and therefore administered to patients along with β-lactam antibiotics [11]. β-lactamases based on molecular structure are classified into four classes according to Ambler scheme such as class A, B, C, and D. Class A family enzymes comprise the largest cluster of β- lactamases known to bear serine residue in their active site and act against various β-lactam antibiotics such as penicillins, early cephalosporins, third-generation oxymino-cephalosporins, monobactams, cephemycins, and carbapenems [12]. Majority of the S. aureus of clinical relevance and few Enterococcus spp. produce blaZ-encoded penicillinases that belong to the class A family [13]. CTX-M (Cefotaximase from Munich), PER (Pseudomonas extended resistant), GES (Guiana extended-spectrum β-lactamase), and VEB (Vietnam extended-spectrum β-lactamase) families belong to class A ESBL enzymes and were found to be produced by all Gram-negative ESKAPE pathogens [14]. The majority of the class A ESBL enzymes can be inhibited by clavulanate except TEM-30 (Temocniera), SHV-10 (Sulphydral reagent variable), and TEM-50 [15]. Alarmingly, some strains of K. pneumoniae were reported to produce inhibitor-resistant β-lactamases (resistant to many known inhibitors of β-lactamase) such as Klebsiella pneumoniae carbenapenase (KPC) enzymes which degrade all β-lactams, including carbapenems [16]. Nevertheless, a combination of imipenem-cilastatin-relebactam or meropenem-vaborbactam was found to be effective against β- lactamases (MBLs) which contain Zn²⁺. The Ambler group B constitutes metallo-β-lactamases (MβLs) which contain Zn²⁺ and are found to be present in ESKAPE pathogens at 2°, 3°, 4°, 6, and 9 positions [24]. Out of five subclasses, ANTs(2°) and ANTs(4°) were reported to be produced by K. pneumoniae and S. aureus respectively. ANTS(2°) confers resistance against 4, 6-di-substituted aminoglycosides whereas ANTS(4°) acts against kanamycin A/B/C, gentamicin A, amikacin, tobramycin, and neomycin B/C [32].

The aminoglycosides are broad-spectrum antibiotics derived from actinomycetes which inhibit protein synthesis by binding to ribosomal subunits. The resistance against these antibiotics majorly occurs through chemical modification by aminoglycoside-modifying enzymes (AMEs) [24]. The genes coding for these enzymes are generally present in the transmissible elements and have rarely been found in genome of some bacteria. The presence of AME activity in resistant bacterial strains has been documented previously [25–27]. The members of the AME family are classified into aminoglycoside acetyltransferases (AACs), aminoglycoside phosphotransferases (APhs), and aminoglycoside nucleotidyltransferases (ANTS) based on the nature of chemical modifications they catalyze [28]. The chemical modifications catalyzed by these enzymes alter the binding affinity of aminoglycosides to ribosomal subunits. Aminoglycoside acetyltransferases are the largest class of AMEs which are further subdivided into four subclasses and are involved in the aminoglycoside antibiotics. AAC(1) and AAC(3) subclasses are involved in the aminoglycoside acetylation of amino groups present in the aminoglycoside antibiotics. Recent epidemiological investigations in the United States, Europe, and Asia revealed that AAC(3) and AAC(6') enzymes are most frequently observed in Gram-negative ESKAPE pathogens which confer resistance against gentamicin, tobramycin, and amikacin [29–31].

APHs are the second largest class of AMEs which are further subdivided into seven subclasses. These enzymes are involved in the phosphorylation of the hydroxyl group present in the aminoglycosides which diminish the binding affinity due to reduced hydrogen bonding interaction between the antibiotic and target. Out of seven subclasses, APH(3') was reported to be found in S. aureus and Enterococcus spp. which confer resistance against amikacin [29].

ANTS are the third-largest class of AMEs which are involved in the addition of nucleotide monophosphate to hydroxyl groups of the aminoglycosides at 2°, 3°, 4°, 6, and 9 positions [24]. Out of five subclasses, ANTS(2°) and ANTS(4°) were reported to be produced by K. pneumoniae and S. aureus respectively. ANTS(2°) confers resistance against 4, 6-di-substituted aminoglycosides whereas ANTS(4°) acts against kanamycin A/B/C, gentamicin A, amikacin, tobramycin, and neomycin B/C [32].

3.2. Prevention of antibiotic influx

The bactericidal efficacy of an antibiotic depends on the amount of drug taken into the bacteria and expelled out. Many antibacterial agents use intracellular targets to impart their growth-inhibitory activity and the maximum efficiency is expected only when a sufficient amount of antibiotic molecule reaches the inner compartments of the cell. Many bacteria have evolved with an adaptive mechanism in which they alter the expression levels of channels and efflux pumps. The outer membrane of Gram-negative bacteria has proteins termed porins that are involved in the formation of channels to enable the movement of antibiotics into the cell. A β-barrel membrane protein (OMP, 29-kDa) was insensitive to imipenem activity [33]. Experimental evidence was provided to demonstrate the role of OprD channel in the influx of panipenem/imipenem. OprD is present in the outer membrane of P. aeruginosa and a decrease in OprD levels enabled the bacteria to acquire resistance against imipenem [34].
3.3. Antibiotic expulsion through efflux pumps

Efflux pumps are responsible for the outflux of antibiotics from the bacterial cell and overexpression of various types of efflux pumps is observed in MDR bacteria. Drug expulsion could be either due to increased expression of efflux pump proteins or base substitution mutation in the gene that codes for the efflux pump protein which may result in the replacement of an amino acid that potentiates the activity of the efflux pump [35]. The genes that encode for efflux pumps can be present either in the bacterial genome or mobile genetic elements such as plasmids. Six families of bacterial drug efflux pumps have been described so far, they are ATP-binding cassette (ABC) family, the multidrug and toxin extrusion (MATE) family, major facilitator superfamily (MFS), the resistance-nodulation-cell division (RND) superfamily, the small multidrug resistance (SMR) family, and the proteobacterial antimicrobial compound efflux (PACE) family [36]. For an instance, *P. aeruginosa* strains are relatively less sensitive to tigecycline and the loss of MexXY (OprM) efflux pumps resulted in the increased sensitivity

![Chemical structures of secondary metabolites derived from bacteria and plants.](image)

**Fig. 2.** Chemical structure of secondary metabolites derived from bacteria and plants.
3.4. Modification of antibiotic target

Bacteria protect themselves from the action of antibiotics through modification of the drug target. The modifications include mutations in the gene that encode target protein, chemical alteration of the interaction site, and substitution of the original target [39]. Many antibiotics impart their antibacterial action by targeting ribosomal subunits (the 30S and 50S). Aminoglycoside antibiotics interact with a 16S rRNA of the ribosome to exploit their antibacterial action by targeting ribosomal subunits (the 30S and 50S) [28]. Some rRNAs (5S and 23S rRNA) and ribosomal proteins of the 50S subunit are targeted by macrolides, ketolides, lincosamides, and streptogramin. Like 16S rRNA methyltransferases, 23S rRNA methyltransferases mediate the antibiotic binding site resulting in the abolishment of antibiotic activity [40]. Similarly, bacterial targets of antibiotics are modified by phosphoethanolamine transferases and peptidoglycan modifying enzymes.

### 4. Antibacterial agents derived from the Mother Nature

Mother Nature has been serving as an inexhaustible source of bioactive secondary metabolites which are endowed with a wide range of pharmacological activities including antibacterial, anticancer, anti-fungal, antihypertensive, antidepressants, antiviral, and many more [41–46]. The structural complexity of these compounds makes the synthetic process impractical. Thousands of secondary metabolites have been isolated from bacteria, plants, fungi, endophytes, and marine microbe towards tigecycline [37]. The members of the RND superfamily such as MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY, and MuxBC—OprB are involved in the expulsion of various antibiotics including β-lactams, aminoglycosides, chloramphenicol, fluoroquinolones, macrolides, quinolones, tetracycline, and novobiocin in *P. aeruginosa* [38]. It can be concluded that all resistant bacteria express their own set of efflux pumps to combat the harmful effects of antibiotics on them.

| Sl. No. | Antibacterial compound | Source | Activity against | Mode of action | Reference |
|---------|------------------------|--------|------------------|----------------|-----------|
| 1.      | Lysobactin             | Several gram-negative | *S. aureus* (MIC - 0.75 µg/mL), MRSA (MIC - 0.39 µg/mL), VRE (MIC - 0.78 µg/mL) | Interferes with peptidoglycan biosynthesis by binding to lipid I, Lipid II, Lipid III cell wall precursors | [164, 165] |
| 2.      | Salinamidine F         | Streptomyces sp., strain CNB-091 | *E. faecalis* (MIC = 12.5 µg/mL), *S. aureus* (MIC = 100 µg/mL), *H. influenzae* (MIC = 12.5 µg/mL), *Nocardiopsis fortis* (MIC = 25 µg/mL), *Enterobacter cloacae* (MIC = 50 µg/mL) | Inhibition of RNA polymerase | [166] |
| 3.      | Siamycin-I            | Streptomyces sp. | VRE (MIC = 7.4 µg/mL), *S. aureus* (MIC = 3.7 µg/mL), MRSA (MIC = 7.4 µg/mL), multidrug resistant *S. aureus* (MIC = 14.8 µg/mL) | Interferes in peptidoglycan biosynthesis by binding to lipid II | [167] |
| 4.      | Capistruin (Lasso peptide) | *Burkholderia thailandensis* Ez264 | *E. coli* 363 (MIC = 25 µg/mL), *P. aeruginosa* AT27853 | Inhibition of RNA polymerase | [168, 169] |
| 5.      | Mitomycin C (7-Amino-Salphen-methoxymitosane) | *Streptomyces coeruleus* | *A. baumannii* (MIC = 7 µg/mL) | DNA intercalation | [170, 171] |
| 6.      | Marthiapetide A (Polythioamide cyclic peptide) | *Marinacinospora thermotolerans* SCSIO 00,652 | *M. lutus* (2.0 µg/mL), *S. aureus* (8 µg/mL) | ND | [172] |
| 7.      | Lobophorin F           | Streptomyces sp. (SCSIO 01,127) | *S. aureus*, *E. faecalis* (MIC for both = 8 µg/mL) | ND | [173] |
| 8.      | Desomatide (Cyclic hexapeptide) | *Streptomyces scopolaidis* SCSIO 9J46 | *S. pneumoniae* (MIC = 12.5 µg/mL), *S. aureus* (MIC = 16 µg/mL), methicillin-resistant *S. epidermidis* (MIC = 32 µg/mL) | ND | [174] |
| 9.      | Abyssomicin C          | *Verticillium sp.* AB-18-032 | MRSA (MIC = 4 µg/mL), MRSA (MIC = 13 µg/mL) | Inhibition of 4-amino-4-deoxychorysosamine (ADC) synthase | [50,51] |
| 10.     | Ficellomyacin          | *Streptomyces fiscellus* | Multidrug resistant strains of *S. aureus* | Interferes in DNA replication | [175] |
| 11.     | Etamycin               | *Streptomyces sp.* | MRSA (MIC = 1-2 mg/L) | Possible role in inhibition of protein synthesis | [176] |
| 12.     | Thiomicarinol A        | *Pseudoluberbonas* sp. SANK 73390 | MRSA (MIC = 0.002 - 0.50 µM) | Inhibition of isoleucyl-RNA synthetase | [177] |
| 13.     | Methramycin           | *Streptomycetes plicatus*, *Streptomycetes argillaceus* | MRSA and MSSA strains (MIC = 0.125 – 0.25 µg/mL) vancomycin resistant enterococci and vancomycin sensitive enterococci (MIC = 1 – 16 µg/mL) | Inhibition of transcription | [178] |
| 14.     | Marinopyrrole A        | *Streptomyces* sp. CNQ-418 | *S. aureus* (MIC = 0.5 – 1 µg/mL), MRSA (MIC = 0.188-0.375 µg/mL), *E. faecalis* (MIC = 1 µg/mL) | ND | [179] |
| 15.     | Bottromycin A2 (Macrocyclic peptide) | *Streptomyces* sp. KM-9459 | *S. aureus* (MIC = 1 µg/mL), MRSA (MIC = 1 µg/mL), VRE (MIC = 1 µg/mL) | Inhibition of protein synthesis | [180] |
| 16.     | Tirandamycin C         | *Streptomyces* sp. 307-9 | VREF | Interferes in RNA polymerase | [181] |
| 17.     | Anthracinimycin B      | *Streptomyces cyanosulcatus* M-1669 | MRSA, MSSA, *E. faecium* | ND | [59] |
| 18.     | Fijimycin A (Cyclic depsipeptide) | *Streptomyces* sp. CNS-575 | MRSA (MIC = 4 – 16 µg/mL) | ND | [182] |
| 19.     | Ecteinamycin          | *Actinomadura* sp. WWMB499 | MRSA (MIC = 0.125 µg/mL), MSSA (MIC = 0.125 µg/mL), *P. aeruginosa* (MIC = 8 µg/mL), *Clostridium difficile* NAP1/B1/027 (MIC = 59 µg/mL) | Acts as an ionophore and is involved in membrane depolarization and dysregulation of potassium cation homeostasis. | [183] |
| 20.     | Lajollamycin          | *S. nodosus* NPS007994, | *S. pneumoniae* (MIC = 1.5 µg/mL), MRSA (MIC = 5 µg/mL) | ND | [184] |

ND: Not determined.
invertebrates and some of them have been approved as therapeutic agents for the treatment of several human ailments [47–49]. Therefore, these biological sources are true treasure houses of secondary metabolites and drugs. In the following sections, we have discussed some of the antibacterial agents derived from bacteria (Fig. 2 and Table 1) and plants (Table 2).

### Table 2

| Sl. No. | Antibacterial compound | Source | Activity against | Mode of action | Reference |
|--------|------------------------|--------|-----------------|----------------|-----------|
| 1      | Resveratrol            | Grapevines (Vitis vinifera), Peanuts (Arachis hypogaea), Japanese knotweed (Polygonum cuspidatum) | S. aureus, E. faecalis, and Streptococcus pyogenes (MIC = 100–200 μg/mL), M. smegmatis (MIC = 64 μg/mL), H. pylori (MIC = 25–50 μg/mL), N. gonorrhoeae (MIC = 75 μg/mL) | Partial inhibition of ATP hydrolysis and synthesis functions of ATP synthase complex. Possible role in the inhibition of FtsZ-mediated septum formation and cell division | [185] |
| 2      | Glabrol                | Licorice (Glycyrrhiza glabra L.) | MRSA T144 (MIC = 2 μg/mL), MSSA 1518 (MIC = 1 μg/mL) | Disruption of membrane permeability, Disipation of proton motive force | [186] |
| 3      | Apigenin               | Parsley (Petroselinum crispum), Chamomile (Matricaria chamomilla L.), Celery (Apium graveolens L.), Vine-sinuphac (Basella rubra L.), Artichokes (Cynara scolymus L.), and Oregano (Origanum vulgare L.) | A. baumannii (HSK 02026 Strain MIC = 2 μg/mL, clinical isolate = 64 μg/mL), E. aerogenes (MIC = 64 μg/mL) | Inhibition of D-alanine-D-alanine ligase and DNA gyrase enzyme | [187–189] |
| 4      | Baicaiolin             | Baikal skullcap (Scutellaria baicalensis), Blue skullcap (Scutellaria lateriflora) | Staphylococcus saprophyticus, Streptococcus mutans E. coli (MIC = 8 μg/mL) | Inhibition of biofilm formation, Inhibition of efflux pump | [190] |
| 5      | Carvacrol              | Conehead thyme (Thymus capitatus) Thyme (Thymus vulgaris) | E. coli (MIC = 8 μg/mL) | Disruption of membrane integrity | [191] |
| 6      | Sanguinarine           | Celandine (Chelidonium majus L.), Blood Root (Sanguinaria canadensis L.), Fumitory (Fumaria officinalis L.) | S. aureus (MIC 1.9 mg/L), MRSA (3.12 μg/mL, clinical isolate = 64 μg/mL) | Release of autolytic enzymes and cell lysis. DNA intercalation leads to inhibition of replication and transcription | [192] |
| 7      | Reserpine              | Sarpaganda or Indian snake root (Rauvolfia serpentina L.) | Staphylococcus sp., Streptococcus sp. Micrococcus sp. | Efflux pump inhibitory activity | [193,194] |
| 8      | Tomatidine             | Tomato (Solanum lycopersicum) | S. aureus, L. monocyogenes, Bacillus sp. | Inhibition of ATP synthase complex | [195] |
| 9      | Sakuranetin            | Acasteae species (Polymina fruticosa, Baccharis retusa), Himalayan cherry (Prunus pumila) | H. pylori (MIC = 87.3 μM) | Inhibition of HpfFABZ enzyme | [196] |
| 10     | Curcumin (Diferuloylmethane) | Turmeric (Curcuma longa) | E. faecalis, S. aureus, P. aeruginosa | Membrane leakage | [197] |
| 11     | Aganyllin              | Finocchioza (Ferulago canepastris) | S. Typhi, E. aerogenes, E.cloacae, S. aureus (MIC = 32 μg/mL) | Inhibition of DNA gyrase enzyme | [198,199] |
| 12     | Conessine              | Kutaja Kurchi (Holarrhena antidysenterica), Kelinda (Holarrhena mitis), False rubber tree (Holarrhena fordiana) | P. aeruginosa, Bacillus sp. | Inhibition of MexAB-OprM efflux pump. | [200–202] |
| 13     | Shikimic acid          | All plants | S. aureus (2.5 mg/mL) | Alteration of membrane potential and leakage of cellular contents, Inhibition of biofilm formation | [203,204] |
| 14     | Ferulic acid           | All plants | E. coli (100 μg/mL), P.aeruginosa (100 μg/mL), S. aureus (1000 μg/mL), L. monocyogenes (1250 μg/mL) | Membrane rupture and release of intracellular contents | [205] |
| 15     | Kaempferol             | Abundant in Tea (Camellia sinensis), Broccoli (Brassica oleraceus), Apple (Malus domestica), Strawberry (Fragaria x ananassa). | S. aureus | Efflux pump inhibition, Inhibition of PriA helicase enzyme, Inhibition of biofilm formation, Inhibition of Sortase A activity | [206–209] |
| 16     | Kurarinol              | Shrubby sophora (Sophora flavescens) | S. aureus (219 μM), E. subtilis (219 μM), S. typhimurium (219 μM), P. vulgaris (109 μM) | Inhibition of Sortase A enzyme | [210] |
| 17     | Morusin                | Mulberry (Morus alba) | S. aureus (14.9 μmol/L) | Disruption of membrane integrity, Reduction gene expression of acc C, Fab D, Fab F, Fab G, Fab H, Fab I, Fab Z, Ptx X, Ptx Y, Ptx C (phosphatidic acid biosynthesis-associated genes) | [211] |
| 18     | Lonicerin              | Japanese honeysuckle (Loniceria japonica) | P. aeruginosa | Inhibition of biofilm formation, Inhibition of alginate secretion protein (AlgE) | [212] |
| 19     | Plumbagin              | Indian leadwort (Plumbago rosea), Ceylon leadwort (Plumbago zeylanica) | S. aureus (5 μg/mL), MRSA (4–8 μg/mL) | Possible role in the inhibition of DNA gyrase | [213–215] |
| 20     | Naringenin             | Present in many citrus fruits such as Grapefruit (Citrus paradisi), Sour orange (Citrus aurantium), tart cherries (Prunus cerasus), tomatoes (Solanum lycopersicum), and greek oregano (Origanum vulgare L.) | E. faecalis (256 μg/mL), VERF (512 μg/mL) | Inhibition of β-Ketoacyl carrier protein synthase (KAS) III (through in silico approach) | [140,216] |

4.1. Abyssomicin C

Abyssomicin C is one of the promising compounds belonging to the family of abyssomicin with antibacterial activity against many Gram-positive bacteria. Abyssomicin C along with its atrop isomer (atrop-abbyssomicin C) and other inactive derivatives such as abyssomicins B and D were isolated from an actinomycete strain Verrucosispora AB-18-
032. The actinomycete strain was isolated from the sediments of the deep Sea of Japan at a depth of 289 m [50]. Abyssomicin C has been reported to possess antibacterial activity against MRSA and VRSA with MIC values of 4 and 13 μg/mL, respectively [51]. The studies of Freundlich et al. demonstrated the antibacterial activity of Abyssomicin C and atrop-abyssomicin C against Mycobacterium tuberculosis H37Rv with MIC values of 3.6 and 7.2 μM, respectively [52]. Abyssomicin C and atrop-abyssomicin C are the first natural compounds reported to inhibit the p-aminobenzoic acid/tetrahydrofolate biosynthesis pathway in Gram-positive bacteria [53,54]. ADC synthase (4-amino-4-deoxychorismic acid synthase) and ADC lyase (4-amino-4-deoxy chorismic acid lyase) are the two important enzymes involved in the biosynthesis of p-aminobenzoic acid from chorismic acid. ADC synthase has two subunits (namely PabA and PabB) which are involved in the conversion of chorismic acid and glutamine to 4-amino-4-deoxy chorismic acid and glutamate, respectively. ADC lyase converts 4-amino-4-deoxy chorismic acid into p-aminobenzoic acid which further participates in the folate biosynthesis. Abyssomicin C and atrop-abyssomicin C independently inhibit the activity of ADC synthase by covalently binding to the side chain of Cys263 of the PabB subunit of ADC synthase [55]. Monjas et al. synthesized truncated derivatives of abyssomycin C and studied their structure-activity relationship towards ADC synthase and these derivatives were found to have lower antibacterial activity compared to abyssomycin C [56].

4.2. Anthracimycin

Anthracimycin was isolated initially in 2013 from the Streptomyces strain CNH365 that was collected from the marine sediments of Santa Barbara, USA. Anthracimycin is a 14-membered macrolide that possesses a rare chemical structure that closely resembles the structure of chlorotetoxin A (antimarial agent). In the initial studies, anthracimycin demonstrated potent antibacterial activity against the Gram-positive organisms such as Bacillus anthracis, S. aureus, Enterococcus faecalis, Streptococcus pneumoniae with MIC values of 0.031, 0.0625, 0.125, 0.25 μg/mL, respectively [57]. Later, anthracimycin was also demonstrated to possess antibacterial activity against the methicillin-susceptible/resistant S. aureus (MSSA/MRSA), and VRSA with MIC values <0.25 μg/mL. In the in vivo studies, anthracimycin protected the mice from MRSA-induced mortality at 1 or 10 mg/kg. They also showed that anthracimycin inhibits the DNA and RNA synthesis in S. aureus and the inhibition is independent of DNA intercalation. Using genome mining strategy, Sirota et al., identified that Nocardiosis kansasensis produces an anthracimycin analog named anthracimycin BI-2619 [58]. Notably, both anthracimycin BI-2619 and anthracimycin displayed antibacterial activity against the MSSA and MRSA with MIC values ≤1 μM. In another study, Rodriguez et al., isolated the anthracimycin B along with anthracimycin from actino-mycete Streptomyces cyanosulcatus M-169 species obtained from gorgonian coral that was collected from Avilés submarine Canyon at 1500 m depth [59]. The anthracimycin B exhibited potent antibacterial activity against MSSA, MRSA, vancomycin sensitive E. faecium, and vancomycin sensitive E. faecalis. Interestingly, Davison et al. developed a method for the chemical synthesis of anthracimycin which opened a new avenue for the synthesis of potent anthracimycin analogs [60].

4.3. Daptomycin

Daptomycin is a cyclic lipopeptide antibiotic produced by Streptomyces roseosporus. It received FDA approval for the treatment of skin infections and S. aureus bacteremia. Daptomycin is the only lipopeptide antibiotic that is in clinical practice and has potent activity against Gram-positive bacterial infections, MRSA, and vancomycin-resistant Enterococci (VRE) [61]. Daptomycin is used as an alternative therapeutic agent to vancomycin for invasive MRSA or MSSA infections in patients who are allergic to β-lactams. It has been considered as a last-resort treatment for heterogeneous vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) infections [62]. Although the precise mechanism of action of daptomycin is yet to be understood, a model proposes that daptomycin interacts with the plasma membrane resulting in its permeabilization and depolarization caused by a loss of cytoplasmic potassium ions [63]. Although daptomycin resistance is uncommon, failure of treatment up to 33% may be observed in invasive infections including bacteremia or osteomyelitis [64]. In one of the interesting studies, S. aureus was demonstrated to release phospholipids in response to daptomycin treatment to sequester the drug and to escape from its bactericidal effects [64]. In a similar study, E. faecalis and pathogenic streptococci were demonstrated to nullify the effect of daptomycin by shedding phospholipids [61]. Considering the therapeutic importance of daptomycin, a large number of studies are being carried out to potentiate its bactericidal action in combination with other antibacterial agents.

4.4. Kibdelomycin

Kibdelomycin is a novel class of antibiotics produced by Kibdelosporangium sp. (MA7385) [65]. S. aureus fitness test strategy was employed for the discovery of kibdelomycin which signifies the importance of a high-throughput chemical genetic approach in the screening of potential natural compounds. The kibdelomycin showed potent antibacterial activity against many Gram-positive organisms such as wild-type S. aureus, MRSA, S. pneumoniae, E. faecalis with MIC values 2, 0.5, 1, and 2 μg/mL, respectively and Haemophilus influenzae (Gram-negative organism) with MIC values of 2 μg/mL. Kibdelomycin was found to impart their antibacterial activity by interrupting DNA replication through the inhibition of ATPase activity of DNA gyrase and topoisomerase IV of Escherichia coli and S. aureus [65]. Subsequently, kibdelomycin A, a congener of kibdelomycin was isolated from Kibdelosporangium sp. (MA7385) and its derivatives (kibdelomycin C-33-actate and tetrahydro-bisdichloro derivative of kibdelomycin) were prepared [66]. Kibdelomycin A and its derivatives were reported to have inferior antibacterial activity compared with kibdelomycin against MSSA, MRSA, S. pneumoniae, E. faecalis, Bacillus subtilis, H. influenzae, E. coli, and Candida albicans [66]. Kibdelomycin A displayed relatively lower inhibitory activity compared to kibdelomycin towards DNA gyrase and topoisomerase IV of S. aureus whereas both the compounds showed similar inhibitory activity towards DNA gyrase and topoisomerase IV of E. coli [66]. Interestingly, co-crystallization studies between kibdelomycin and gyrase B or topoisomerase IV of S. aureus revealed that kibdelomycin exhibits a “dual-arm” U-shaped binding mode with both enzymes [67]. Kibdelomycin is a wide-spectrum antibiotic without cross-resistance to known gyrase inhibitors, including clinically effective quinolones. The ‘dual arm’ U-shaped binding interaction of kibdelomycin is unique and not seen in other gyrase inhibitors [67]. This may be the reason to present kibdelomycin as an antibiotic without cross-resistance to other gyrase inhibitors. Beside, kibdelomycin was reported with potent antibacterial activity against Clostridium difficile, a causative agent of C. difficile-associated diarrhea, especially in elderly people [68]. Kibdelomycin acted as a broad range bactericidal agent and found to be effective against the Gram-negative organisms such as Moraxella catarrhalis and A. baumannii with MIC90 values of 0.5 and 0.125 μg/mL, respectively. Taken together, kibdelomycin can be considered as the potential antimicrobial compound against many pathogenic bacteria [69].

4.5. Platensimycin

Platensimycin and platencin are produced by Streptomyces platensis that represents a unique structural class of non-toxic natural antibiotics [70]. Platensimycin has been identified as an effective inhibitor of bacterial fatty acid synthases by selectively targeting β-ketoacyl-(a-cyl-carrier-protein (ACP)) synthase I/II [71]. The discovery of
platensimycin has provided a new direction to the discovery of antibiotics with structural diversity. MRSA biofilms in wounds are difficult to treat with conventional antibiotics. Platensimycin and sulfur-Michael derivatives suppressed the biofilm formation by S. aureus beyond 95% at 2 μg/mL [72]. Notably topical application of ointments having platensimycin was successful in treating MRSA infections in a BALB/c mouse burn wound model [72]. However, its clinical development was hindered due to its poor solubility and pharmacokinetic properties. To overcome these shortcomings, several efforts have been made including the preparation of platensimycin nanoformulations. In one such study, platensimycin-loaded nanoparticles substantially decreased residual bacteria relative to free platensimycin in the MRSA-infected macrophage cell model [73]. Notably, encapsulation of platensimycin with liposomes or micelles significantly enhanced its pharmacokinetic properties in Sprague–Dawley rats with an increase in the survival rate of MRSA-infected C57BL/6J mice [73]. These studies suggest that pitfalls of platensimycin may be overcome either through its chemical modifications or the utilization of better delivery systems.

4.6. Plazomicin

Plazomicin ([6-(hydroxyethyl)-1-(haha)-sisomicin] is a next-generation semisynthetic aminoglycoside antibiotic that originated from sisomicin which was isolated from Micromonospora inyensis [74]. Plazomicin obtained approval from the US Food and Drug Administration for the treatment of complicated urinary tract infections caused by Gram-negative aerobic bacteria. Importantly, plazomicin is a relatively efficacious aminoglycoside towards carbapenem-resistant Enterobacteriaceae and ESBL-producing Enterobacteriaceae [75,76]. The positively charged plazomicin belongs to the class of aminoglycosides. These classes of antibiotics penetrate the periplasm of bacteria by interacting with the negatively charged cell membrane [77,78]. Further with the help of oxygen-nitrogen dependant electron chain machinery, they enter the aerobic bacteria [77]. The plazomicin is an inhibitor of protein synthesis and showed synergistic activity in combination with the cefepime, doripenem, imipenem, or piperacillin-tazobactam against P. aeruginosa.

5. Antibiotics from plant origin

5.1. Allicin

Allicin (diallylthiosulfinate) is an organosulfur compound present in the garlic (Allium sativum L.) which is endowed with good antibacterial activity against MRSA, Pseudomonas syringae, Salmonella typhimurium, and Vibrio cholerae [94]. Allicin is synthesized from the non-protein amino acid named alliin by the enzyme alliinase in the garlic [95]. Allicin is a volatile compound and it was used to treat some infections of the respiratory system in the pre-antibiotic era. The antimicrobial effect of the allicin is imparted through its inhibitory activity towards the thiol group-containing enzymes such as alcohol dehydrogenase, thioredoxin reductase, and RNA polymerase [96]. The electrophilic sulfur center of allicin is a volatile compound and it was used to treat some infections of the respiratory system in the pre-antibiotic era. The antimicrobial effect of the allicin is imparted through its inhibitory activity towards the thiol group-containing enzymes such as alcohol dehydrogenase, thioredoxin reductase, and RNA polymerase [96]. The electrophilic sulfur center of the allicin readily oxidizes thiol groups of the target enzymes to form S-allylmercapto adduct and thereby leads to inactivation of these enzymes. Allicin has also been shown to partially inhibit the synthesis of DNA and proteins. The possible reason for translation inhibition is due to the reaction of allicin with thiol groups of elongating amino acid chains on ribosomes [97]. Some investigations have revealed that allicin augments the antibacterial activity of some of the antibiotics such as cefoperazone, tobramycin, and ciprofloxacin, against P. aeruginosa [98]. Despite being a good antibacterial agent, it is unstable at room temperature and antimicrobial activity is lost within minutes upon heating to >80 °C. The thiosulfinate analogs of allicin such as dimethyl-, diethyl-, diallyl-, dipropyl-, and dibenzyl-thiosulfonates were reported to have variable antibacterial activity against E. coli K12, Pseudomonas fluorescens, and P. syringae pv. phaseolicola 4612, Micrococcus luteus, and were found to be much more thermally stable than allicin [99].

5.2. Berberine

Berberine is a phytogenous isoquinoline alkaloid present in the plants that belong to the family of Berberidaceae, Papaveraceae, and Ranunculaceae [100]. The antibacterial property of berberine is extensively reported in the literature and its age-old usage in traditional Chinese and Ayurvedic medicinal systems against bacterial infections is well-documented. The antibacterial activity of berberine is mediated through diverse mode-of-actions such as intercalation of DNA, inhibition of enzymes (such as RNA polymerase, gyrase, and topoisomerase IV), and blockage of cell division [101]. The antibacterial activity of
berberine and in combination with the antibiotics such as ampicillin and oxacillin against the clinical isolates of MRSA was studied and berberine inhibited the growth of MRSA with MIC values ranging from 32 to 128 μg/mL [102]. It has also been identified that berberine decreases the MRSA adhesion and intracellular invasion to the cultured monolayers of human gingival fibroblasts. The antibacterial activity of berberine alone and in combination with ampicillin or oxacillin resulted in additive and synergistic effects against MRSA isolates respectively [102]. In another study, berberine (30–45 μg/mL) induced antibacterial activity and inhibited the biofilm formation in Staphylococcus epidermidis [103]. Berberine also inhibited the biofilm formation in other organisms such as C. albicans, S. pythiumarium, and S. aureus [104–106]. Chu et al. provided the mechanistic insight for the inhibition of biofilm formation in MRSA by berberine. It was revealed that berberine inhibits biofilm formation in a dose-dependent manner (1 to 64 μg/mL) by disrupting the aggregation of phenol-soluble modulins (PSMs) into amyloid fibrils [107]. PSMs are a family of amphipathic, α-helical peptides present in staphylococci and have drawn attention due to their involvement in the virulence of S. aureus. PSMs are involved in biofilm development which is thought to have a prominent role in staphylococcal colonization [108]. Berberine displayed a synergistic antibiotic effect with azithromycin against the clinical isolates of P. aeruginosa [109]. The combination of berberine and azithromycin significantly reduced the production of virulence factors such as α-lactalbumin, LasA protease, LasB protease, poyverdin, pyocyanin, chitinase, and extracellular DNA. In addition, the combination also inhibits the expression of quorum-sensing-related genes such as lasR, lasR, rhlR, and rhlR. Recently, Li et al., demonstrated that berberine exhibit the synergistic effect with sodium houttuyfonate against the MRSA and VISA, and the effect is likely to be mediated through interruption of the cell membrane [110]. Overall, these reports suggest that berberine has the potential to be developed as a drug that can be administered along with other clinically approved antibacterials.

5.3. Biochanin A

Biochanin A (5,7-dihydroxy-4′-methoxy isoflavone) is majorly present in the soybean, chickpea, peanuts, Indian rosewood, etc. It was initially isolated from red clover (Trifolium pratense L.), which belongs to the Fabaceae family [111]. Biochanin A showed a synergistic effect in combination with ciprofloxacin against clinical isolates of S. aureus and also reduced the NorA gene expression in MRSA indicating that biochanin A may suppress the efflux of antibiotics [112,113]. In an interesting study, Lechner et al. examined the antibacterial effect of several plant phenolic compounds (such as baicalin, baicain, biochanin A, daidzein, formononetin, genistein, luteolin, myricetin, resveratrol, chlorpromazine, reserpine, and verapamil) through ethidium bromide efflux assay in Mycobacterium smegmatis. Out of all these compounds, only biochanin A potentiated the effects of ethidium bromide and demonstrated efflux inhibition comparable to standard efflux pump inhibitors [114]. Biochanin A displayed the selective growth inhibitory effect towards Clostridium spp. over Bifidobacterium spp. [115]. The antibacterial activity of biochanin A was reported against pathogenic organisms such as Leishmania chagasi (EC₅₀ = 18.96 μg/mL), and Chlamydia pneumoniae (EC₅₀ = 12 μM) [116,117]. An inclusion complex of biochanin A with (2-hydroxypropyl)-β-cyclodextrin was prepared to enhance its aqueous solubility and its antibacterial examination against E. coli and K. pneumoniae did not display significant activity over pure biochanin A [118]. Recently, the pharmacological effects of biochanin A have been thoroughly reviewed by Sarfraz et al. [111]. Only a limited number of studies have reported the antimicrobial activity towards ESKAPE organisms. Many more studies are essential to comprehensively demonstrate the mode-of-action of this compound.

5.4. Caffeic acid and its derivatives

Caffeic acid is a phenolic compound present in many plant commodities such as olives, cinnamon, nutmeg, blueberries, apple, star anise, etc. [119]. Chemically, caffeic acid is a 3, 4-dihydroxy cinnamic acid-containing phenylpropanoid with hydroxyl groups at the third and fourth position of the aromatic ring [120]. The plant system contains monomeric, dimeric, and trimeric forms of caffeic acid such as organic acid esters, sugar esters, amides, glycosides, etc. The caffeic acid is endowed with diverse pharmacological properties such as antibacterial, antiviral, anti-inflammatory, antioxidant, antiatherosclerotic, immune-stimulatory, antidiabetic, cardioprotective, antiproliferative, hepatoprotective, anticancer, and many other activities. The poor aqueous solubility and lack of stability are the major limitations of caffeic acid and some of its derivatives. They get degraded rapidly in vivo and in vivo setup and hence attempts were made to encapsulate caffeic acid and its derivatives into nanoparticles to increase the water solubility. Caffeic acid conjugated with chitosan exhibited a synergistic antibacterial effect in combination with antibiotics such as tetracycline, erythromycin, and lincomycin against S. aureus, S. epidermidis, P. aeruginosa, Propionibacterium acnes [121]. The observed growth inhibitory effects of the conjugates could be due to the alteration of bacterial membrane permeability. Caffeic acid-coated polymeric fibrous materials such as poly(3-hydroxybutyrate) and poly(ethylene glycol) showed antibacterial activity against S. aureus and E. coli and they were proposed to be useful in controlling wound infections [123]. To address the solubility and stability issues of caffeic acid, several nano-formulations of caffeic acid were made and their antibacterial activity was studied. The caffeic acid immobilized on zinc oxide nanoparticles showed strong antimicrobial activity against S. aureus, MRSA, and E. coli [124]. The encapsulation of caffeic acid with cyclodextrins improved the solubility of caffeic acid and was found to have enhanced antibacterial activity against the K. pneumoniae and S. aureus [125].

The caffeic acid phenethyl ester (CAPE) exhibited antibacterial activity against both Gram-positive and Gram-negative organisms such as S. aureus, Streptococcus mutans, Streptococcus mitis, Bacillus megatatum, B. subtilis, Lactobacillus acidophilus, etc. [126]. In another study, CAPE displayed remarkable antimicrobial activity against common oral cariogenic bacteria (S. mutans, Streptococcus sobrinus, Actinomyces viscosus, and L. acidophilus) [127]. Additionally, CAPE inhibited the formation of S. mutans biofilms and their metabolic activity in mature biofilms. CAPE has been reported to induce antibacterial effects through various mechanisms including permeabilization of the cell membrane, alteration of membrane transport, membrane depolarization, and inhibition of bacterial RNA polymerase [128]. The caffeic acid entrapped in silica gel matrix presented good antibacterial activity against E. faecalis and E. coli. In view of all these studies, caffeic acid and its derivatives are emerging as potential antibacterial agents against a wide variety of bacteria.

Chlorogenic acid is one of the naturally occurring derivatives of caffeic acid seen in coffee, tea, apples, pears, carrots, tomatoes, sweet potatoes, grapes, etc. Chlorogenic acid is a major constituent of some traditional Chinese medicinal preparations and is endowed with many medicinal properties including antibacterial activity against many Gram-positive and Gram-negative organisms [129,130]. A significant synergetic bactericidal and antibiofilm effect was produced against S. aureus by the combination of ultrasound and chlorogenic acid treatment which was mediated through increasing the cell membrane permeability, release of ATP, and nucleic acids, and decreasing the exopolysaccharide contents in the biofilm [131]. Similarly, chlorogenic acid presented strong bactericidal and antibiofilm activity in the clinical
isolates of *Stenotrophomonas maltophilia* including the trimethoprim/sulfamethoxazole resistant strain [132]. The antimicrobial effects of caffeine, its combinational uses, and synthetic strategies have been thoroughly reviewed recently [119]. These reports suggest that the caffeine derivatives or structural analogs could serve as potent chemicals against bacteria with pathological relevance.

5.5. Piperine

Piperine is one of the primary alkaloids present in the black pepper (*Piper nigrum* L.) and long pepper (*Piper longum* L.). The piperine was first isolated by Hans Christian Ørsted in 1819 from the extracts of pepper as a yellow crystalline compound. The IUPAC name of piperine is 1-(5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl)piperidine and it is present in four isomeric forms such as piperine, isopiperine, chavicine, and isochavicine [133]. Some of the piperine analogs were reported as the inhibitors of NorA efflux pumps in *S. aureus* [134]. Multidrug efflux pumps are the leading player for bacterial antibiotic resistance due to their involvement in the expulsion of antibiotics out of the cell. NorA multidrug-resistant efflux pump contributes to the reduced susceptibility of *S. aureus* to antibiotics [135]. Notably, inhibition of efflux pumps using natural and synthetic compounds has emerged as an important strategy to counteract bacterial multidrug resistance [136]. Piperine potentiated the effect of ciprofloxacin against *S. aureus* which resulted in a two-fold reduction of the MIC value of ciprofloxacin [137]. The nanoliposomes with co-loaded piperine and gentamicin displayed good antibacterial activity with almost a 32-fold reduction of MIC value compared to free gentamycin against the MRSA [138] and these activities are proposed to be imparted through the inhibition of efflux pumps [134]. These reports emphasize the efflux pump inhibitory activity of piperine and the need for its evaluation with other antibiotics against drug-resistant organisms.

5.6. Taxifolin

Taxifolin is chemically known as 3,5,7,3,4-pentahydroxy flavanone or dihydroquercetin, a polyphenolic flavonoid, which is majorly present in plants such as *Silybum marianum*, *Allium cepa*, *Pseudotsuga taxifolia*, and *Pinus pinaster*. Taxifolin possesses diverse medicinal properties such as anti-inflammatory,anticancer,antiantiogenic,hepatoprotective,etc. Taxifolin was found to have antibacterial activity against *S. sobrinus*, a pathogen responsible for dental caries, with an IC50 value of 21.8 ± 1.7 μg/mL [139]. It also showed good inhibition towards glucosyltransf erase derived from *S. sobrinus* with an IC50 value of 53.0 ± 0.7 μg/mL [139]. The inhibition of glucosyltransferase is one of the strategies in the prevention of dental caries and this report suggests that taxifolin can be developed as a potent agent for preventing dental caries. Taxifolin inhibited the growth of *E. faecalis* and VREF with MIC values of 128 and 512 μg/mL, respectively [140]. Based on the docking studies, the authors demonstrated that β-ketoacyl acyl carrier protein synthase III, a key enzyme in bacterial fatty acid biosynthesis, is the potential target of taxifolin with a binding affinity of 6.76 × 10^{-7} M^{-1} [140]. In another study, the antibacterial activity of taxifolin was evaluated at 0.5, 1.0, 2.0, and 5.0% concentrations against *E. coli*, *S. epidermidis*, *P. aeruginosa*, and *M. luteus* and out of which *S. epidermidis* displayed high sensitivity to taxifolin at 5% concentration [141]. DNA gyrase and aminocycl-tRNA synthetases are the bacterial enzymes crucial for DNA replication and protein synthesis, respectively. Eight flavonoids were investigated for their inhibitory activity towards DNA gyrase and isoleucyl-tRNA synthetase on a molecular docking platform and taxifolin was identified as a lead inhibitor [142]. They also reported that taxifolin interacts with a good number of amino acids at the active sites of DNA gyrase and aminocycl-tRNA synthetase of *M. tuberculosis* based on the in silico molecular docking and dynamics simulation approach. Additionally, taxifolin displayed antimycobacterial activity against *M. tuberculosis* with a MIC value of ≤ 12.5 μg/mL [142]. In a recent investigation, taxifolin was reported as the inhibitor of sortase A of MRSA, an enzyme essential for bacterial colonization in the host tissues [143]. Taxifolin is also believed to be effective against many Gram-positive organisms which demand further investigation [143].

5.7. Thymol

Thymol (also known as 2-isopropyl-5-methylphenol) is a primary monoterpane present in the essential oils of plants belonging to the genera of Thymus, Ocimum, Origanum, Satureja, Thymbra, and Monarda. The usage of essential oils of these plants as a flavoring and preservative agent is an age-old practice in the food industry. The FDA has listed the thymol and other components present in these essential oils as ‘generally recognized as safe’ (GRAS) for their supplementation in food products [144]. Many studies reported the antibacterial activity of essential oils that are rich in thymol against various Gram-positive and Gram-negative organisms. Thymol presented antibacterial activity against clinical isolates and standard cultures of MRSA and *S. epidermidis* and the results showed that all isolates were susceptible to thymol with MIC values ranging from 0.03 to 0.06% (v/v) [145]. Thymol displayed antibacterial activity against *S. aureus* and *E. coli* with a MIC of 0.31 and 5.0 mg/mL respectively and mode-of-action analysis revealed that thymol influences the permeability of the lipid membrane of the bacteria which results in leakage of cellular contents [146]. Xu et al. showed that thymol induces bactericidal activity against *E. coli* through the permeabilization and depolarization of the bacterial cytoplasmic membrane. They showed the potential use of flow cytometry as a tool for the investigation of the mode of antibacterial action of essential oil components [147]. The chemical derivatives of thymol were examined for antibacterial effect against *S. mutans*, *S. aureus*, *B. subtilis*, *S. epidermidis*, and *E. coli*. Thymol acetate (2-isopropyl-5-methylphenyl acetate), thymol propionate (2-isopropyl-5-methylphenyl propionate), and thymol isobutyrate (2-isopropyl-5-methylphenyl isobutyrate) displayed consistent activity against all the Gram-positive strains [148]. The effect of thymol against *Salmonella* spp. biofilm on polypropylene was examined. Thymol suppressed bacterial counts about 1–2 log during biofilm formation, reduction of about 1–5 log in the established biofilms [149]. These results suggest the antibiofilm potential of thymol against *Salmonella* spp. which can be examined in other bacterial systems. In another study, thymol imparted antibacterial activity towards *S. aureus*, *S. epidermidis*, *B. cereus*, *E. coli*, *P. aeruginosa*, *E. faecalis*, *Vibrio parahaemolyticus*, *Vibrio alginolyticus*, and *Salmonella enteritidis* with MIC values ranging between 32 and 64 μg/mL [150]. Additionally, thymol reduced the MIC values of tetracycline and benzalkonium chloride towards these microorganisms. Thymol induced the intracellular accumulation of ethidium bromide in a dosage-dependent manner indicating that thymol may sensitize bacteria to antibiotics through the inhibition of efflux pumps [150]. Marchese et al. thoroughly reviewed the antibacterial and antifungal effects of thymol and its derivatives [144]. Taken together, thymol or its derivatives may be developed as antibacterials towards drug-sensitive/-resistant microbes.

6. Conclusion and future perspectives

ESKAPE organisms are posing a life-threatening condition in the global context and the discovery of new potent antibiotics against these organisms is the need of the hour. ESKAPE organisms are heterogenous at the genetic level, but share common resistance mechanisms such as the chemical modification or breakdown of the drug, prevention of antibiotic influx, antibiotic expulsion through efflux pumps, modification of antibiotic target, etc. It is a global challenge for the discovery of novel potent bacterial agents with favorable toxicity profiles. Many pathogenic bacteria are developing various strategies to counteract the bactericidal effect of most effective antibiotics through different mechanisms which pose an alarm for the need for newer antibiotics. It is important to note that, a large number of secondary metabolites have
been isolated from bacteria, fungi, plants, and marine invertebrates and have been developed as potent drugs against various human ailments [151–155]. Over 13,000 natural compounds have been isolated from bacterial sources indicating that these microorganisms remain a treasure house of bioactive compounds [156,157]. Beside, about 70% of these natural compounds have been extracted from actinomycetes (a group of Gram-positive mycelial bacteria) and merely 1% of actinomy- ceetes have been cultured so far indicating the abundance of hidden bioactive compounds in the bacterial kingdom. It is highly essential to speed up the discovery of bioactive compounds from unexplored bacterial and plant sources [158–161]. Antibiotic discovery faces several constraints. Since from 1960s, very few classes of antibiotics were discovered such as quinolones, lincosamides, oxazolidinones, and cyclic lipopeptides which still have a major share in the world’s global antibiotic market [162]. Beside, novel antibiotics that were discovered later on were all majorly derived from established antibiotic classes and they are used as last-resort antibiotics which further discouraged the investment in antibiotic drug discovery research by many pharmaceutical industries [163]. In addition, the expensive operational cost of clinical trials poses a significant constraint in the R & D of antimicrobial drug design. Despite these constraints, several alternate strategies are employed in the current antibiotic research to counter the antimicrobial resistance of ESKAPE organisms. Combinatorial drug therapy is one such strategy where adjuvants are used along with the antibiotics to improve the patient response. To combat against the threatening antimicrobial resistance of ESKAPE organisms, other various novel strategies utilized nowadays are repurposing of drugs, monoclonal antibody therapy, vaccine development, bacteriophage therapy, etc. Along with these various strategies, concerted efforts are needed in the global and regional platforms in policymaking, funding, guidelines for appropriate use of antibiotics, diagnostics and treatment, and employment strategies applied against ESKAPE pathogens to keep the antimicrobial resistance mechanisms of these organisms under surveillance and control.

Declaration of Competing Interest

I, Prof Rangappa on behalf of all the co-authors declare that there is no conflict of interest associated with this study. I also declare that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. I also declare that the manuscript has been solely submitted to Biotechnology Reports and it is not under consideration in any other journal for publication.

References

1 C. Walsh, Antibiotic: Actions, Origins, Resistance, American Society for Microbiology (ASM), 2003.
2 H. Gelband, P. Molly Miller, S. Pant, S. Gandra, J. Levinson, D. Barter, A. White, M. Rossolini, Cloning and characterization of bla VIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate, Antimicrob. Agents Chemother. 43 (7) (1999) 1584–1596.
3 Y. Matsunaga, G. Takebayashi, J. Spencer, I. Iorga, Beta-lactamase database (BLDB) -structure and function, J. Enzym. Inhib. Microb. Technol. 22 (1) (2007) 917–915.
4 C.L. Tooko, P. Hinchcliffe, E.C. Bragginton, C.K. Colenso, V.J.A. Hirvonen, Y. Takebayashi, J. Spencer, β-Lactamases and β-Lactamase inhibitors in the 21st century, J. Mol. Biol. 431 (18) (2019) 3472–3500, https://doi.org/10.1016/j.jmb.2019.04.002.
5 K. Bush, G.A. Jacoby, Updated functional classification of β-lactamases, Antimicrob. Agents Chemother. 54 (3) (2010) 969–976.
6 S. Santajit, N. Indrawattana, Mechanisms of antimicrobial resistance in ESKAPE pathogens, J. Glob. Antimicrob. Updates 13 (6) (2010) 151–1026.
7 W.F. Shi, J.P. Jiang, Z.H. Mi, Relationship between antimicrobial resistance and antibiotic use in China, Ann. N.Y. Acad. Sci. 1020 (2004) 225–248.
8 T. Naas, S. Oueslati, R.A. Bonnin, M.L. Dabos, A. Zavala, L. Dortet, P. Retailleau, B. I. Jorga, Beta-lactamase database (BLDB)-structure and function, J. Enzym. Inhib. Microb. Technol. 22 (1) (2007) 917–915.
59 V. Rodríguez, J. Martín, A. Sarmiento-Vizcaíno, M. De la Cruz, L.A. García, G. Blanco, F. Reyes, Anthracycin B, a potent antibiotic against gram-positive bacteria isolated from the ocean, J. Antibiot. 65 (2012) 511-515.
60 E.K. Davison, J.L. Freeman, W. Zhang, W.M. Wuest, D.P. Furrert, M.A. Brimble, Asymmetric Total Synthesis of the Naturally Occurring Antibiotic Anthracycin B, Antimicrob. Agents Chemother. 55 (6) (2011) 2229–2233.
61 V. Cañas, S. Scarpacchi, E. Lo Verde, I. De Guidi, A. Zega, G. Pigna, S. Stefani, Genomic and long-term transcriptomic imprints related to the daptomycin mechanism of action in daptomycin- and methylcillin-resistant staphylococcus aureus under daptomycin exposure, Front. Microbiol. 11 (2020) 1–15.
62 R.A. Seaton, F. Menichetti, G. Dalekos, A. Beiras-Fernandez, F. Nacinovich, R. Pathan, K. Hamed, Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European clinical outcomes registry and experience, Adv. Ther. 32 (12) (2015) 1192–1205, https://doi.org/10.1007/s12325-015-0267-4.
63 V. Pader, S. Hakim, K.L. Painter, S. Wigneshwaranj, T.B. Clarke, A.M. Edwards, Staphylococcus aureus inactivated by daptomycin releasing phospholipids, Nat. Microbiol. 2 (2016) 1619, https://doi.org/10.1038/nmobi.2016.194.
64 J.W. Phillips, M.A. Goetz, S.K. Smith, D.L. Zink, J. Poliashock, R. Onishi, S. Salowe, J. Wilkins, J. Allocco, J. Sigmund, Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus, Chem. Biol. 18 (8) (2011) 955–965.
65 S.B. Singh, M.A. Goetz, S.K. Smith, D.L. Zink, J. Poliashock, R. Onishi, S. Salowe, J. Wilkins, J. Allocco, C. Sarmiento-Vizcaíno, A. Bender, Kibdelomycin derivatives and their antibacterial activities, Bioorg. Med. Chem. Lett. 22 (23) (2012) 7112–7116.
66 J. Liu, S. Patel, N. Sharma, S.M. Soinski, R. Kishi, M. Takei, Y. Fukuda, K.J. Lamb, S. Singh, Structures of antibodies bound to Staphylococcus aureus in the context of the semi-natural product daptomycin against breast cancer cells, Biochimie 182 (2021) 140–151, https://doi.org/10.1016/j.biochi.2021.01.009.
67 C.O. Mohan, M.H. Yang, S. Ranagapa, A. Chinnathambi, S.A. Alharbi, T. A. Alahmad, A. Deivasigamani, R. Kishi, S.K. Sivasegaran, K.S. Ahn, 3-formylchromone counteracts STAT3 signaling pathway by elevating SHP-2 expression in hepatocellular carcinoma, J. Cancer Res. Ther. 16 (2020) 83–94, https://doi.org/10.1007/s12325-020-00704-6.
68 K.O. Manu, M.K. Shammugam, L. Ramachandran, F. Li, C.W. Fong, A.P. Kumar, P. Tan, G.R. Sethi, First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capetitabine in a xenograft mouse model through the modulation of NF-κB pathway, Clin. Cancer Res. 18 (8) (2012) 2220–2229, https://doi.org/10.1158/1078-0432.CCR-11-2470.
69 K.S. Ahn, G. Sethi, M.M. Chatrvedi, B.B. Aggarwal, Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of the janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma, J. Cell. Physiol. 226 (2011) 2215–2227, https://doi.org/10.1002/jcp.23009.
70 E.K. Davison, J.L. Freeman, W. Zhang, W.M. Wuest, D.P. Furrert, M.A. Brimble, Asymmetric Total Synthesis of the Naturally Occurring Antibiotic Anthracycin B, Antimicrob. Agents Chemother. 55 (6) (2011) 2229–2233.
71 L. Miesel, D.W. Hecht, J.R. Omololu, D. Gerding, A. Flattery, J.D. Poliashock, L. Lanz, Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile, Antimicrob. Agents Chemother. 58 (4) (2014) 2387–2392.
72 S.B. Singh, P. Dayananth, C.J. Balbir, C.G. Garlisi, J. Lu, R. Kishi, M. Takei, Y. Fukuda, S. Isha, K. Young, Kibdelomycin A is a beta-cocarboxylic acid bacterial antibiotic agent, Antimicrob. Agents Chemother. 59 (6) (2015) 3474–3481.
73 E. Martens, A.L. Demain, Platensimycin and platencin: promising antibiotics for future application in human medicine, J. Antibiot. 64 (11) (2011) 705–710, https://doi.org/10.1038/ja.2011.80.
74 J. Wang, S.M. Soinski, K. Young, W. Shopo, K. Galgoci, R. Painter, G. Parthasarathy, Y.S. Tang, R. Cummings, S. Ha, K. Dorsoy, M. Motluy, H. Jayasuriya, J. Ondeyka, K. Herath, C. Zhang, L. Hernandez, J. Allocco, A. Basilio, J.R. Tormo, L. Liang, Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile, Antimicrob. Agents Chemother. 58 (4) (2014) 2387–2392.
75 K.S. Ahn, G. Sethi, H. Zahn, B. Krisner, A.T. Bull, L.A. Maldonado, A. C. Ward, M. Goodfellow, B. Bister, D. Biohoff, Abyssoycinins, inhibitors of the paraaobenzonic acid pathway produced by the marine Vaccinobacter sp strain AB-18-032, J. Antimicrob. 60 (6) (2007) 391–394.
76 J. Riedlinger, A. Reiche, H. Zahn, B. Krisner, A.T. Bull, L.A. Maldonado, A. C. Ward, M. Goodfellow, B. Bister, D. Biohoff, Abyssoycinins, inhibitors of the paraaobenzonic acid pathway produced by the marine Vaccinobacter sp strain AB-18-032, J. Antimicrob. 60 (6) (2007) 391–394.
77 P. Dozzo, H.E. Moser, New aminoglycoside antibiotics, Expert Opin. Ther. Pat. 20 (10) (2010) 1321–1332.
78 V. Denervaud-Tendon, L. Poirel, L.E. Connolly, K.M. Krause, P. Nordmann, V. Rodríguez, J. Martín, A. Sarmiento-Vizcaíno, M. De la Cruz, L.A. García, G. Blanco, F. Reyes, Anthracycin B, a potent antibiotic against gram-positive bacteria isolated from the ocean, J. Antibiot. 65 (2012) 511-515.
79 K.H. Jang, S.J. Nam, J.B. Locke, A.P. Kumar, L.A. Paul, W. Fenical, Anthracycin B, a potent antibiotic against gram-positive bacteria isolated from the ocean, J. Antibiot. 65 (2012) 511-515.
80 M. Thwaites, D. Hall, D. Shinabarger, A. Serio, K. Krause, A. Marra, C. Pillar, Recent progress on the development of antibiotics against the genus Micromonopora, Biotechnol. Bioprocess Eng. 21 (2) (2016) 199–223.
81 P. Dozzo, H.E. Moser, New aminoglycoside antibiotics, Expert Opin. Ther. Pat. 20 (10) (2010) 1321–1332.
82 R.M. Hower, S.H. Kim, M. Katz, Z. Charlop-Powers, J.G. Owen, M.A. Termei, J. Maniko, A.B. Estrela, H. Molina, S. Park, D.S. Perlin, S.F. Brady, Asymmetric Total Synthesis of the Naturally Occurring Antibiotic Anthracycin B, Antimicrob. Agents Chemother. 55 (6) (2011) 3481.
83 D Deng, Y. Weng, X. Li, Y. Su, M. Wen, Z. Xi, N. Ren, S. Shen (2019) Late-stage functionalization of platensimycin leading to multiple analogues with improved antibacterial activity in vitro and in vivo. (https://doi.org/10.1021/acs.jmedchem.0c00616).
84 A.Z. Boumehira, H.A. El-Enshasy, H. Hacioglu, E.A. Elsayed, R. Aziz, E.Y. Park, Recent progress on the development of antibiotics against the genus Micromonopora, Biotechnol. Bioprocess Eng. 21 (2) (2016) 199–223.
Biotechnology Reports 34 (2022) e00728

10 G. X. Wei, X. Xu, C. D. Wu, X. Wang, X. Yao, T. Tang, K. Dai, I. Sadovskaya, S. Flahaut, S. Jabbouri, Effect of berberine on Staphylococcus epidermidis biofilm formation, Int. J. Antimicrob. Agents 34 (1) (2009) 60–65.

11 Y. Li, P. Wang, X. Hu, Y. Zhang, X. Lu, C. Li, T. Nie, G. Li, X. Wang, J. Pang, The combined antibacterial and biocidal effects of berberine chloride against growing and persistent methicillin-resistant and vancomycin-intermediate Staphylococcus aureus, BMC Microbiol. 20 (1) (2020) 1–11.

12 A. Sarrafzad, M. Javed, M.A. Shah, G. Hussain, N. Shadig, A. Sarrafzad, A. Riaz, A. Siddiqua, R. Zara, S. Zafar, Biochanin A: a novel bioactive multifunctional compound from nature, Sci. Total Environ. 722 (2020), 137907.

13 G. Liu, J.C. Liang, X.L. Wang, Z.H. Li, W. Wang, N. Guo, X.P. Wu, F.G. Shen, M. X. Li, In vitro synergistic activity of biochanin A and ciprofloxacin against clinical isolates of Staphylococcus aureus. Molecules 16 (8) (2011) 6656–6666.

14 D. Zou, K. Xie, H. Wang, Y. Chen, X. Mie, Inhibitory effects of biochanin A on the eflux pump of methicillin-resistant Staphylococcus aureus (MRSA), Wei sheng wu xue bao—Acta Microbiol. Sin. 54 (10) (2014) 1204–1211.

15 D. Lechner, S. Gibbons, F. Bucar, Plant phenolic compounds as ethidium bromide efflux inhibitors in Mycobacterium smegmatis, J. Antimicrob. Chemother. 62 (2) (2008) 345–349.

16 O. Sklenickova, J. Plener, L. Kosoka, E. Vikola, K. Halamova, J. Malik, Selective growth inhibitory effect of biochanin A against intestinal tract colonizing bacteria, Molecules 15 (10) (2010) 1270–1279.

17 P. Sartorelli, C.S. Carvalho, J.Q. Reimao, M.J.P. Ferreira, A.G. Tempone, Antimicrobial activity of biochanin A, an isolated isolavone from fruits of Cassia fistula (Leguminosae), Parasitol. Res. 104 (2) (2009) 311–314.

18 L. Hanski, N. Genina, H. Uvell, K. Malinovskaya, A. Gyfle, T. Laksoren, R. Kolokolov, E. Malka, J. Salonen, H. Hirvonen, Inhibitory activity of the isolavone biochanin A and its glucuronidated metabolites in an initial development of a buccal formulation, PLoS One 12 (9) (2014), e115115.

19 L.I. Nikolic, M.I. Savic, M.M. Popasavic, S.J. Rakic, T.M. Mihajlov-Krstev, I. Ristic, S.P. Eric, I.M. Savic-Gajic, Preparation, characterization and antimicrobial activity of inclusion complex of biochanin A with β-cyclodextrin-β-cyclodextrin, J. Pharm. Pharmacol. 70 (11) (2018) 1485–1493, https://doi.org/10.1111/jphp.13003.

20 F. Khan, N.I. Hamann, S. Tabassum, T.Y. Kim, Caffeic acid and its derivatives: antimicrobial drugs toward microbial pathogens, J. Agric. Food Chem. 69 (10) (2021) 2979–3004.

21 T. Silva, C. Oliveira, F. Borges, Caffeic acid derivatives, analogs and applications: a patent review (2009–2013), Expert Opin. Ther. Pat. 24 (11) (2014) 1257–1270.

22 D. Novakovic, J. Petrovic, M. Savcevic, J. Glamo, M. Kolačkoski, S. Petrovic, In situ and antimicrobial activities of naturally occurring caffeic acid, p-coumaric acid and rutin, using food systems, J. Sci. Agric. Food. 93 (13) (2013) 3205–3208.

23 J.H. Kim, D. Yu, S.H. Eom, S.H. Kim, J. Oh, W.K. Jung, Y.M. Kim, Synergistic antibacterial effects of chitosan-caffeic acid conjugate against antibiotic-resistant acnec-related bacteria, Mar. Drugs 15 (6) (2017) 167.

24 M. Ignatova, N. Manolova, I. Rashkov, N. Markova, Quaternated chitosan-β-cyclodextrin/caffeic acid-coated poly (3-hydroxybutyrate) fibril materials: preparation, antibacterial and antioxidant activity, Int. J. Pharm. 513 (1–2) (2016) 528–537.

25 K.H. Choi, K.C. Nam, S.Y. Lee, G. Cho, J.S. Jung, H.J. Kim, B.J. Park, Antioxidant potential and antibacterial efficiency of caffeic acid-functionalized ZnO nanoparticles, Nanomaterials 7 (6) (2017) 148, https://doi.org/10.3390/ nanomater7060148 (Basel).

26 E. Phito, G. Squires, M. Henrques, Evaluation of antibacterial activity of caffeic acid encapsulated by β-cyclodextrin, J. Microencapsul. 32 (8) (2015) 804–810.

27 S. Meynahu, M. Assali, M. Huleihel, M. Huleihel, Antibacterial activities of caffeic acid phenethyl ester, J. Mol. Microbiol. Biotechnol. 4 (2) (2015).

28 Y. Ni, K. Wang, S. Zheng, Y. Wang, Q. Ren, H. Li, L. Ding, W. Li, L. Zhang, Antibacterial effect of caffeic acid phenethyl ester on cariogenic bacteria and streptococcus mutans biofilms, Antimicrob. Agents Chemother. 66 (2020)

29 J.J. Veloz, M. Alvez, L.A. Salazar, Antimicrobial and antiinflammatory activity against Streptococcus mutans of individual and mixtures of the main polyphenolic compounds found in Chilean propolis, Biomed. Res. Int. (2019), 2019.

30 G. Li, X. Wang, Y. Xu, B. Zhang, X. Xia, Inhibitory effect and mode of action of chlorogenic acid on Staphylococcus aureus, Eur. Food Res. Technol. 238 (4) (2014) 589–596.

31 Á. Luís, F. Silva, S. Sousa, A.P. Duarte, F. Domingues, Antistaphylococcal and biofilm inhibitory activities of gallic, caffeic, and chlorogenic acids, Biofactors 39 (1) (2014) 69–79, https://doi.org/10.1002/biof.201348578.

32 J. Sun, D. Wang, Z. Sun, F. Liu, L. Du, D. Wang, The combination of ultrasonic and chlorogenic acid to inactivate Staphylococcus aureus under planktonic, biofilm, and food systems, Ultrasom. Sonochim. 80 (2021), 105801, https://doi.org/10.1016/j.ultras.2021.105801.

33 A. Karunaidhri, R. Thomas, A. van Beekel, V. Neela, In vitro antibacterial and antiinflammatory activities of chlorogenic acid against clinical isolates of Stenotrophomonas maltophilia including the trimethoprim/sulfamethoxazole resistant strain, Biomed. Res. Int. 2013, 392850.

34 L. Gorgani, M. Mohammadi, G.D. Najafpour, M. Nikzad, Pipercine—the bioactive compounds of black pepper: a review, Medical Medicinal Com, Rev. Food Sci. Food Saf. 17 (1) (2017) 124–146.
182 P. Sun, R.K. Maloney, S.J. Nam, N.M. Haste, R. Raju, W. Aalbersberg, P.R. Jenen, V. Nizet, M.E. Hendler, W. Fenical, Fijimycins A–C, three antibacterial etamycin-class desippeptides from a marine-derived Streptomyces sp, Biphylog. Med. Chem. 19 (22) (2011) 6557–6562.

183 T.P. Wyche, R.F.R. Alvaranga, J.S. Piotrowski, M.N. Duster, S.R. Warrack, G. Cornelles, T.J. De Wolfe, Y. Hou, D.R. Braun, G.A. Ellis, Chemical genomics, structure elucidation, and in vivo studies of the marine-derived antistreptolysin eicemanycin, ACS Chem. Biol. 12 (9) (2017) 2287–2295.

184 R.R. Manam, S. Teisan, D.J. White, B. Nicholson, J. Grodborg, S.T. Neuteboom, K. S. Lam, D.A. Mosca, G.K. Lloyd, B.C. Potts, Lajollamycin, a Nitro-tetraene Spiro- lactone–lactam Antibiotic from the Marine Actinomucete Streptomyces odousus, J. Nat. Prod. 68 (2) (2005) 240–243.

185 M. Vestergaard, H. Ingmer, Antibacterial and antifungal properties of resveratrol, Int. J. Antimicrobi. Agents 53 (6) (2019) 716–723.

186 S.C. Wu, Z.Q. Yang, F. Liu, W.J. Peng, S.Q. Ou, Q. Li, X.B. Song, K. Zhu, J.Z. Shen, Antibacterial effect and mode of action of flavonoids from licorice against methicillin-resistant Staphylococcus aureus, Front. Microbiol. 10 (2019) 2489.

187 B. Ozel, M. Kartal, I. Orhan, Cytotoxicity, antiviral and antimicrobial activities of alkaloids, flavonoids, and phenolic acids, Pharm. Biol. 49 (4) (2011) 396–402.

188 A. Basile, S. Sorbo, S. Giordano, L. Ricciardi, S. Ferrara, D. Montesano, R. B. Taranto, A. Basile, S. Sorbo, S. Giordano, L. Ricciardi, S. Ferrara, D. Montesano, R. B. Taranto, Antimicrobial and antioxidant activities of coumarins from the roots of Ferulago caput-medusae, J. Nat. Prod. 68 (2005) 240–243.

189 I. Gómez, R. Bartoszewski, J. Królczewski, Comprehensive review of antimicrobial activities of plant flavonoids, Phytochem. Rev. 18 (1) (2019) 241–272.

190 J. Wang, H. Jiao, J. Meng, M. Qiao, H. Du, M. He, K. Ming, J. Liu, D. Wang, Y. Wu, Baicalin inhibits biofilm formation and the quorum-sensing system by regulating the Msra drug efflux pump in Staphylococcus saprophilicus, Front. Microbiol. 10 (2019) 2800.

191 O.Y. Althunibat, H. Qaralleh, S.Y.A. Al-Dalin, M. Abboud, K. Khleifat, I.S. Majali, A. Basile, S. Sorbo, V. Spadaro, M. Bruno, A. Maggio, N. Faraone, S. Rosselli, M. Lamontagne-Boulet, C. Isabelle, I. Guay, E. Brouillette, J.P. Langlois, A. Basile, S. Sorbo, S. Giordano, L. Ricciardi, S. Ferrara, D. Montesano, R. B. Taranto, Antimicrobial and antioxidant activities of plant flavonoids, Phytochem. Rev. 18 (1) (2019) 241–272.

192 R. Jadimurthy et al.

193 T. Siriyong, P. Sirinanote, S. Chusri, B.E. Yingyongnarongkul, C. Suaisom, V. Tipparanee, S.P. Varavuthikunchai, Conesine as a novel inhibitor of multidrug efflux pump systems in Pseudomonas aeruginosa, BMC Complement. Altern. Med. 17 (1) (2017) 1–7.

194 K. Patrice, P.B. Veronique, L. David, E. Francois-Vivar, Antibacterial activities of the extracts and conessine from Holarrhena floribunda G. Don. (Apocynaceae), Afr. J. Tradit. Complement. Altern. Med. 4 (3) (2007) 352–356.

195 J. Bai, Y. Wu, X. Liu, K. Zhong, Y. Huang, H. Gao, Antibacterial activity of shikimic acid from pine needles of cedrus deodara against staphylococcus aureus through damage to cell membrane, Int. J. Mol. Sci. 16 (11) (2015) 27145–27155.

196 J.R. Bai, K. Zhong, Y.P. Wu, G. Elena, H. Gao, Antimicrobial activity of shikimic acid against staphylococcus aureus, Food Control 95 (2019) 327–333.

197 A. Borges, C. Ferreira, M.J. Saaedver, M. Simon, Antibacterial activity and mode of action of ferulic and gallic acids against pathogenic bacteria, Microb. Drug Resist. 19 (4) (2013) 256–265.

198 S.M. Someren, L. Johannet, Dietary flavonoid sources in Australian adults, Nutr. Cancer 60 (4) (2008) 442–449.

199 D. Ming, D. Wang, F. Cao, H. Xiang, D. Mu, J. Cao, B. Li, L. Zhong, X. Dong, Z. Xiang, Kaempferol inhibits the primary attachment phase of biofilm formation in Staphylococcus aureus, Front. Microbiol. 8 (2017) 2263.

200 A.R. Brown, K.A. Ettefagh, D. Todd, P.S. Cole, J.M. Egan, D.H. Feil, T.N. Graf, B. D. Schindler, G.W. Kaiz, N.B. Cech, A mass spectrometry-based assay for improved quantitative measurements of efflux pump inhibition, PLoS One 10 (5) (2015), e0124814.

201 Y.H. Huang, C.C. Huang, C.C. Chen, K.J. Young, C.Y. Huang, Inhibition of staphylococcus aureus PrA helicase by flavon kaempferol, Protein J. 34 (3) (2015) 169–172.

202 I. Oh, W.Y. Yang, S.C. Chung, T.Y. Kim, K.B. Oh, J. Shin, In vitro sortase A inhibitory and antimicrobial activity of flavonoids isolated from the roots of Sophora flavescens, Arch. Pharm. Res. 34 (2) (2011) 217–222.

203 D. Pang, S. Liao, W. Wang, L. Mu, E. Li, W. Shen, F. Liu, Y. Zou, Destruction of the cell membrane and inhibition of cell phosphatidic acid biosynthesis in Staphylococcus aureus: an explanation for the antibacterial mechanism of morusin, Food Funct. 10 (10) (2019) 6438–6446.

204 Z. Xu, K. Li, T. Pan, J. Liu, B. Li, C. Li, S. Wang, Y. Xiao, X. Liu, Lonicerin, an anti-agglutination agent: from chemistry to medicine, Stud. Nat. Prod. Chem. 65 (2019) 201–216.

205 A. Ahmad, H. Madkhali, Naringenin (4, 5, 7-trihydroxyflavanone) as a potent neuroprotective agent: from chemistry to medicine, Stud. Nat. Prod. Chem. 65 (2019) 201–216.

206 T. Siriyong, P. Srimanote, S. Chusri, B.E. Yingyongnarongkul, C. Suaisom, B. Singh, P. Bhandari, A.P. Gupta, V.K. Kaul, Steroidal alkaloids from Stereum hirsutum, J. Nat. Prod. 68 (2) (2005) 240–243.

207 D. Pang, S. Liao, W. Wang, L. Mu, E. Li, W. Shen, F. Liu, Y. Zou, Destruction of the cell membrane and inhibition of cell phosphatidic acid biosynthesis in Staphylococcus aureus: an explanation for the antibacterial mechanism of morusin, Food Funct. 10 (10) (2019) 6438–6446.

208 A. Ahmad, H. Madkhali, Naringenin (4, 5, 7-trihydroxyflavanone) as a potent neuroprotective agent: from chemistry to medicine, Stud. Nat. Prod. Chem. 65 (2019) 201–216.

209 A. Ahmad, H. Madkhali, Naringenin (4, 5, 7-trihydroxyflavanone) as a potent neuroprotective agent: from chemistry to medicine, Stud. Nat. Prod. Chem. 65 (2019) 201–216.